Slider oncology

Breast Cancer

Breast Cancer

The discovery of the ER and HER2 as cancer therapeutic targets ushered in the paradigm of precision medicine for patients with breast cancer with considerable success in early-stage disease. Advances in HER2 targeted therapies have also improved survival of patients with HER2-positive disease, but a significant proportion of these patients develop metastasis, which remain the principal cause of death for patients with breast cancer. Until very recently, a major challenge in drug development had been the lack of identifying breast cancer targets based on well validated gene drivers in breast cancer, with the exception of ER, ESR1, HER-2, PIK3CA and ATK1 biomarkers. In this regard, the Menarini team and collaborators, has been analyzing the genomic and immune landscape of patients with metastatic breast cancer and validating potential therapeutic targets in the preclinical and clinical settings. 

oncology